Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Julia-Tatjana Maul

University Hospital of Zurich

Switzerland

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacotherapy

100%

Pharmacology

40%

Dermatology

100%

Psoriasis

100%

Pharmacoepidemiology

40%

Anti-inflammatory Research

40%

Drug Repurposing

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles25

Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study

Article Link

Year:

2025

The Prevalence and Severity of Hand Eczema Among Adults in Tasiilaq, East Greenland

Article Link

Year:

2025

Preferences in atopic dermatitis: A systematic review

Article Link

Year:

2025

Prevalence of risk factors affecting the use of oral JAK inhibitors in hidradenitis suppurativa

Article Link

Year:

2025

Deucravacitinib: Long‐term safety and efficacy reaffirm its place in the psoriasis treatment landscape

Article Link

Year:

2025

Beyond the surface: Integrating sex and gender in dermatologic therapy

Article Link

Year:

2025

Characteristics and management of generalized pustular psoriasis (<scp>GPP</scp>): Experience from the Central and Eastern Europe (<scp>CEE</scp>) <scp>GPP</scp> Expert Network

Article Link

Year:

2024

Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort study

Article Link

Year:

2024

Impact of the pre‐biologic treatment journey on biologic drug survival in psoriasis: A nationwide cohort study

Article Link

Year:

2024

Prevalence of ichthyoses in Denmark: a nationwide registry-based study

Article Link

Year:

2024

Cracking the code: unveiling the nexus between atopic dermatitis and addictive behavior: a cross-sectional exploration of risk factors

Article Link

Year:

2024

Guselkumab in Patients with Scalp Psoriasis: A post hoc Analysis of the VOYAGE 2 Phase III Randomized Clinical Trial

Article Link

Year:

2024

Patient and dermatologists' perspectives on augmented intelligence for melanoma screening: A prospective study

Article Link

Year:

2024

Global Comparison of COVID-19 Vaccination Rates among Psoriasis Patients

Article Link

Year:

2024

No impact of disease duration on response to tildrakizumab treatment among patients with moderate‐to‐severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies

Article Link

Year:

2023

Speed of clinical improvement in the real‐world setting from patient‐reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks

Article Link

Year:

2023

Predicting discontinuation of biologic therapy caused by adverse events in psoriasis patients—A Danish nationwide cohort study

Article Link

Year:

2023

Attitudes towards COVID Vaccine and Vaccine Hesitancy in Dermatology: A Narrative Review

Article Link

Year:

2023

Acceptance of Telemedicine Compared to In-Person Consultation From the Providers' and Users’ Perspectives: Multicenter, Cross-Sectional Study in Dermatology

Article Link

Year:

2023

Mapping the road to biologics in psoriasis and psoriatic arthritis: A nationwide drug utilization study

Article Link

Year:

2023

Identifying the potential origin of mucin in primary cutaneous mucinoses—A retrospective study and analysis using histopathology and multiplex fluorescence staining

Article Link

Year:

2023

Cutaneous lichenoid drug eruptions: A narrative review evaluating demographics, clinical features and culprit medications

Article Link

Year:

2023

Disease burden of moderate–severe atopic dermatitis by use of systemic treatment: Results from the Danish Skin Cohort

Article Link

Year:

2023

Prevalence of and association between atopic dermatitis and food sensitivity, food allergy and challenge‐proven food allergy: A systematic review and meta‐analysis

Article Link

Year:

2023

Drug Survival of Adalimumab, Secukinumab, and Ustekinumab in Psoriasis as Determined by Either Dose Escalation or Drug Discontinuation during the First 3 Years of Treatment – a Nationwide Cohort Study

Article Link

Year:

2023

Collaborators22

Lone Skov

DENMARK

Andreas Pinter

University Hospital Frankfurt

GERMANY

Simon F. Thomsen

DENMARK

Margaret Huang

University of Florida

UNITED STATES

Su Lwin

Dermatology Registrar, Honorary Lecturer

UNITED KINGDOM

Constanze Jonak

AUSTRIA

S. M. Müller

SWITZERLAND

A. Reich

POLAND

Tiago Torres

University of Porto

PORTUGAL

Gantenbein Lorena

University Hospital Basel

SWITZERLAND

Lars French

Professor and Chairman

Ludwig-Maximilians-Universität München

GERMANY

Diamant Thaçi

University of Lübeck

GERMANY

jose-manuel carrascosa

head of department, associated professor

Hospital Universitari Germans Trias i Pujol

SPAIN

Christoph Schlapbach

SWITZERLAND

Nikolai Loft

DENMARK

John R Ingram

Cardiff University

UNITED KINGDOM

Trine Bertelsen

Aarhus University Hospital

DENMARK

Hazel Oon

Head, Psoriasis Unit

SINGAPORE

Jashin J. Wu

UNITED STATES

Peter Schmid-Grendelmeier

Head Allergy Unit

Spital Davos AG

SWITZERLAND

Barbara Meier-Schiesser

SWITZERLAND

Jacob Pontoppidan Thyssen

DENMARK

How do I reach out?

Meet Kite AI